Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the
"Company"), an eyecare technology company focused on developing and
commercializing innovative, interventional technologies intended to
transform care and improve patients' lives, today reported
financial results for the fourth quarter and full year ended
December 31, 2023, and initiated financial guidance for full year
2024.
Recent Financial Highlights
- Generated full year 2023 total revenue of $81.1 million, an
increase of 14% compared to full year 2022 and generated fourth
quarter 2023 total revenue of $18.8 million, a decrease of 9%
compared to the same period in the prior year.
- Reduced fourth quarter 2023 operating expenses to $27.1
million, a reduction of $6.8 million, or 20%, and reduced non-GAAP
adjusted operating expenses1,2 to $22.3 million, a reduction of
$8.3 million, or 27%, compared to the same period in the prior
year.
- Reduced cash used in 2023 to $46.9 million, reflecting
continued operational discipline and an improvement from $75.7
million cash used in 2022. Reduced cash used to $6.4 million in the
fourth quarter of 2023 compared to $10.0 million used in the third
quarter of 2023, a decrease of 36%, and $14.8 million used in the
fourth quarter of 2022, a decrease of 57%.
- In January 2024, announced the closing of a senior secured
credit facility for up to $65.0 million with Hercules Capital,
including an initially funded $35.0 million tranche under the
facility, strengthening the Company’s balance sheet with improved
commercial terms while maintaining current debt outstanding.
Recent Business and Clinical
Highlights
- Maintained Medicare patient access to the OMNI® Surgical System
(“OMNI”) and the SION® Surgical Instrument (“SION”) following a
comprehensive review and subsequent withdrawal of final local
coverage determinations (“LCDs”) by five Medicare Administrative
Contractors (“MACs”), resulting in no change to the current
Medicare coverage for minimally invasive glaucoma surgery (“MIGS”)
procedures.
- GEMINI 2, a three-year, prospective, multicenter, medication
washout clinical trial was published in Clinical Ophthalmology,
demonstrating OMNI procedures delivered sustained and significant
intraocular pressure (mean of 29% IOP reduction at 36 months) and
medication reductions (74% of study patients medication-free at 36
months).
- SAHARA, a six-month, multicenter, randomized controlled trial
was published in Clinical Ophthalmology, demonstrating successful
clinical trial results comparing our TearCare® technology to
Restasis® for the treatment of Dry Eye Disease, showing
interventional eyelid procedures enabled by TearCare technology
successfully delivered clinically and statistically significant
improvements in every sign and symptom at all measured time points
through six months.
Management Commentary
"We are extremely proud of our achievements in
2023 and our team’s remarkable resilience, focus, and determination
throughout a challenging LCD process in the back half of the year
that ultimately resulted in the LCDs being withdrawn. We added
highly experienced medtech growth leadership to our team,
restructured our commercial organization for both increased
efficiency and effectiveness, and meaningfully reduced our cash
burn during a transient period of uncertainty, which I believe will
lead to predictable long-term results as we enter our next exciting
phase of transformative growth,” said Paul Badawi, co-founder and
Chief Executive Officer of Sight Sciences.
“We believe we have multiple catalysts to be
excited about in 2024. We plan to expand the library of clinical
data demonstrating the differentiated safety and efficacy profiles
of our interventional glaucoma and dry eye technologies, make
significant progress towards meaningful reimbursement for TearCare,
and based on the productive start to the year we expect to return
to double-digit revenue growth in the second half of 2024 with our
elevated commercial infrastructure and strategy,” continued Mr.
Badawi.
Fourth Quarter 2023 Financial
ResultsRevenue for the fourth quarter of 2023 was $18.8
million, a decrease of $1.8 million, or 9%, compared to the same
period in the prior year. Surgical Glaucoma revenue was $17.2
million, a decrease of 9% compared to the same period in the prior
year. While customer retention was solid, the uncertainty resulting
from the LCDs, which have now been withdrawn, was the primary
driver of lower utilization and new account additions in the fourth
quarter of 2023 versus the same period in the prior year. Dry Eye
revenue was $1.6 million, a decrease of 11% from the same period in
the prior year. The decline was primarily due to the evolution of
the Company’s commercialization strategy for its Dry Eye segment,
which emphasizes driving higher utilization within existing
accounts to cultivate long-term recurring revenue, and the reduced
sales infrastructure implemented as a result of the Company’s
reorganization and cost-reduction measures taken in October
2023.
Gross profit for the fourth quarter of 2023 was
$16.0 million compared to $16.9 million in the same period in the
prior year. Gross margin for the fourth quarter of 2023 was 85%,
compared to 82% in the same period in the prior year. The increase
in gross margin was primarily driven by a prior year inventory
charge for legacy components in the Company’s Surgical Glaucoma
segment and continued manufacturing efficiencies compared to the
prior year, partially offset by product sales mix. Surgical
Glaucoma gross margin in the fourth quarter of 2023 increased to
88%, compared to 84% in the same period in the prior year,
primarily driven by the prior year inventory charge described above
and manufacturing efficiencies compared to the prior year,
partially offset by production variances and lower ASPs due to
product sales mix. Dry Eye gross margin in the fourth quarter of
2023 declined to 53%, compared to 59% in the same period in the
prior year, primarily due to inventory reserve charges in the
current period, partially offset by manufacturing efficiencies
compared to the prior year.
Total operating expenses were $27.1 million in
the fourth quarter of 2023 representing a 20% decrease compared to
$33.9 million in the same period in the prior year, which reflects
reduced research and development operating expenses and selling,
general, and administrative operating expenses in the comparative
periods, and improved operating expense leverage. Research and
development expenses were $3.4 million in the fourth quarter of
2023 compared to $5.2 million in the same period in the prior year,
representing a 35% decrease in the comparative periods. Selling,
general, and administrative expenses were $23.7 million in the
fourth quarter of 2023, compared to $28.7 million in the same
period in the prior year, representing an 18% decrease in the
comparative periods. Adjusted operating expenses1,2 were $22.3
million in the fourth quarter of 2023, down from $30.6 million in
the same period in the prior year.
Net loss was $10.7 million ($0.22 per share) in
the fourth quarter of 2023, compared to $16.9 million ($0.35 per
share) in the same period in the prior year.
Cash and cash equivalents totaled $138.1 million
and total long-term debt was $35.0 million (before debt discount
and amortized debt issuance costs) as of December 31, 2023,
compared to $144.5 million and $35.0 million respectively as of
September 30, 2023. Cash used in the quarter totaled $6.4 million,
reflecting continued operational discipline and a sequential
improvement from $10.0 million cash used in the third quarter of
2023 and a decrease versus the comparative period in the prior year
where cash used in the fourth quarter of 2022 was $14.8
million.
Full Year 2023 Financial
ResultsRevenue for full year 2023 was $81.1 million, an
increase of $9.7 million, or 14%, compared to full year 2022.
Surgical Glaucoma revenue was $74.3 million, an increase of 13%
compared to the prior year, and Dry Eye revenue was $6.7 million,
an increase of 18% compared to the prior year.
Gross profit for full year 2023 was $69.2
million, compared to $59.0 million in 2022. Gross margin for the
full year 2023 was 85%, compared to 83% in the prior year. Gross
margin improvement was primarily attributable to manufacturing cost
reductions and higher production volumes covering largely fixed
allocated manufacturing overhead.
Total operating expenses were $126.4 million in
2023, representing a 12% decrease compared to $142.9 million in
2022, reflecting reduced research and development operating
expenses and selling, general, and administrative operating
expenses in the comparative periods, and improved operating expense
leverage. Adjusted operating expenses1,2 were $110.3 million for
full year 2023, down from $128.5 million in the prior year.
Net loss was $55.5 million ($1.14 per share) for
full year 2023, as compared to $86.2 million ($1.80 per share) in
2022.
Cash and cash equivalents totaled $138.1 million
and total long-term debt was $35.0 million (before debt discount
and amortized debt issuance costs) as of December 31, 2023,
compared to $185.0 million and $35.0 million as of December 31,
2022. Cash used in full year 2023 totaled $46.9 million, reflecting
continued operational discipline and an improvement from $75.7
million cash used in 2022.
Subsequent to year end, the Company announced
the closing of a new senior secured credit facility of up to $65.0
million. The Company drew an initial $35.0 million from the
facility to refinance its existing senior credit facility while
maintaining its current debt outstanding. The new facility provides
the Company the ability to draw up to an additional $30.0 million,
subject to the satisfaction of certain
conditions. 2024
Financial GuidanceSight Sciences projects revenue for full
year 2024 to range from approximately $81.0 million to $85.0
million, representing a range of 0% to 5% growth compared to 2023.
The Company expects double-digit revenue growth in the second half
of 2024 versus the comparable periods in the prior year as it
regains commercial momentum and expands utilization and its
customer base.
The Company expects full year 2024 adjusted
operating expenses1,3 of approximately $107.0 million to $110.0
million, representing a range of 0% to 3% decline compared to 2023,
with higher first quarter adjusted operating expenses expected
primarily due to higher legal expenses for pending litigation.
The Company's full year 2024 financial guidance
is forward-looking in nature, reflecting our expectations as of
March 7, 2024, and is subject to significant risks and
uncertainties that limit our ability to accurately forecast
results. This outlook assumes no meaningful changes to the
Company's business prospects or risks and uncertainties identified
by management that could impact future results, which include, but
are not limited to: changes in the reimbursement environment,
including coverage decisions and reimbursement rates; the outcome
of clinical trials; the outcome of legal proceedings or regulatory
matters; changes in economic conditions, including discretionary
spending and inflationary pressures; and supply chain disruptions,
constraints and related expenses.
1 “Adjusted operating expenses” is a financial
measure not prepared in accordance with the generally accepted
accounting principles in the United States (“GAAP,” and such
measure, a “non-GAAP financial measure”), and is calculated as
operating expenses less stock-based compensation expense,
depreciation and amortization, and restructuring costs. Please see
the “Non-GAAP Financial Measures” section below for additional
information.2 A reconciliation of the GAAP financial measures to
the most directly comparable non-GAAP financial measures has been
provided in the table titled "GAAP to Non-GAAP Reconciliation"
attached to this press release.3 Consistent with Securities and
Exchange Commission regulations, the Company has not provided a
reconciliation of forward-looking non-GAAP financial measures to
the most directly comparable GAAP financial measures in reliance on
the “unreasonable efforts” exception set forth in the applicable
regulations, because there is substantial uncertainty associated
with predicting any future adjustments that may be made to the
Company’s GAAP financial measures in calculating the non-GAAP
financial measures.
Non-GAAP Financial
MeasuresCertain non-GAAP financial measures, including
adjusted operating expenses are presented in this press release to
provide information that may assist investors in understanding the
Company's financial and operating results. The Company believes
these non-GAAP financial measures are important performance
indicators because they exclude items that are unrelated to, and
may not be indicative of, the Company's core financial and
operating results. These non-GAAP financial measures, as
calculated, may not necessarily be comparable to similarly titled
measures of other companies and may not be appropriate measures for
comparing the performance of other companies relative to the
Company. These non-GAAP financial measures are not intended to
represent, and should not be considered to be more meaningful
measures than, or alternatives to, measures of operating
performance as determined in accordance with GAAP. To the extent
the Company utilizes such non-GAAP financial measures in the
future, it expects to calculate them using a consistent method from
period to period.
Conference Call Sight Sciences'
management team will host a conference call today, March 7, 2024,
beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so
by accessing a live and archived webcast of the event at
www.sightsciences.com, on the Investors page in the News &
Events section. The webcast will be available for replay for at
least 90 days after the event.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional solutions intended to
transform care and improve patients' lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world's most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company's OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and the cutting of trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world's leading cause of irreversible blindness. The Company's
TearCare System technology is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”) when used in conjunction with manual expression
of the meibomian glands, enabling clearance of gland obstructions
by physicians to address the leading cause of dry eye disease. The
Company's SION® Surgical Instrument is a manually operated device
used in ophthalmic surgical procedures to excise trabecular
meshwork.
For more information,
visit http://www.sightsciences.com.
Sight Sciences and TearCare are trademarks of Sight Sciences
registered in the United States. OMNI and SION are trademarks of
Sight Sciences registered in the United States, European Union and
other territories.
Restasis is a registered trademark of Allergan,
an AbbVie company.© 2024 Sight Sciences. All rights reserved.
Forward-Looking StatementsThis
press release, together with other statements and information
publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The Company intends
such forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with these safe harbor
provisions. Any statements made in this press release or during the
earnings call that are not statements of historical fact, including
statements about our beliefs and expectations, are forward-looking
statements and should be evaluated as such. Forward-looking
statements include, but are not limited to, statements concerning
our ability to achieve or maintain coverage for our products; our
ability to leverage clinical evidence to maintain and expand
patient access to and utilization of our technologies; our belief
that we are well-positioned to drive long-term growth in our
segments; our ability to continue reducing our cash burn and
improve our operational efficiencies to expand our operating
leverage over future periods; our ability to capture the benefits
from our commercial reorganization; our access to and use of our
senior secured credit facility; and our projected 2024 revenue and
adjusted operating expenses guidance.. These statements often
include words such as "anticipate," "expect," “suggests,” “plan,”
“believe,” “intend,” “estimates,” “targets,” “projects,” “should,”
“could,” “would,” “may,” “will,” “forecast” and other similar
expressions. We base these forward-looking statements on our
current expectations, plans and assumptions we have made in light
of our experience in the industry, as well as our perceptions of
historical trends, current conditions, expected future developments
and other factors we believe are appropriate under the
circumstances at such time. Although we believe these
forward-looking statements are based on reasonable assumptions at
the time they are made, you should be aware that many factors could
affect our business, results of operations and financial condition
and could cause actual results to differ materially from those
expressed in the forward-looking statements. These statements are
not guarantees of future performance or results. These
forward-looking statements are subject to and involve numerous
risks, uncertainties and assumptions, including those discussed
under the caption “Risk Factors” in our filings with the U.S.
Securities and Exchange Commission, as may be updated from time to
time in subsequent filings, and you should not place undue reliance
on these statements. These cautionary statements are made only as
of the date of this press release. We undertake no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by applicable law.
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Media contact: pr@SightSciences.com
SIGHT SCIENCES, INC.Condensed Consolidated
Balance Sheets (Unaudited)(in thousands, except
share and per share data) |
|
|
|
|
|
|
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
138,129 |
|
|
$ |
185,000 |
|
Accounts receivable, net of allowance for credit losses of $1,186
and $1,024 at December 31, 2023 and 2022, respectively |
|
|
14,289 |
|
|
|
15,148 |
|
Inventory, net |
|
|
7,849 |
|
|
|
6,114 |
|
Prepaid expenses and other current assets |
|
|
2,604 |
|
|
|
3,415 |
|
Total current assets |
|
|
162,871 |
|
|
|
209,677 |
|
Property and equipment, net |
|
|
1,640 |
|
|
|
1,571 |
|
Operating lease right-of-use
assets |
|
|
1,458 |
|
|
|
1,614 |
|
Other noncurrent assets |
|
|
682 |
|
|
|
211 |
|
Total assets |
|
$ |
166,651 |
|
|
$ |
213,073 |
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,731 |
|
|
$ |
2,688 |
|
Accrued compensation |
|
|
4,528 |
|
|
|
7,352 |
|
Accrued and other current liabilities |
|
|
3,774 |
|
|
|
7,777 |
|
Current portion - long-term debt, net |
|
|
2,219 |
|
|
|
— |
|
Total current liabilities |
|
|
12,252 |
|
|
|
17,817 |
|
Long-term debt, net of current
portion |
|
|
31,708 |
|
|
|
33,313 |
|
Other noncurrent liabilities |
|
|
2,476 |
|
|
|
1,867 |
|
Total liabilities |
|
|
46,436 |
|
|
|
52,997 |
|
Commitments and
contingencies |
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Preferred stock, par value $0.001 per share; 10,000,000 shares
authorized; no shares issued and outstanding as of December 31,
2023 and 2022, respectively |
|
|
— |
|
|
|
— |
|
Common stock, par value $0.001 per share; 200,000,000 shares
authorized; 49,131,363 and 48,298,138 shares issued and outstanding
as of December 31, 2023 and 2022, respectively |
|
|
49 |
|
|
|
48 |
|
Additional paid-in-capital |
|
|
414,956 |
|
|
|
399,271 |
|
Accumulated deficit |
|
|
(294,790 |
) |
|
|
(239,243 |
) |
Total stockholders’ equity |
|
|
120,215 |
|
|
|
160,076 |
|
Total liabilities and stockholders’ equity |
|
$ |
166,651 |
|
|
$ |
213,073 |
|
SIGHT
SCIENCES, INC.Condensed Consolidated Statements of
Operations and Comprehensive Loss (Unaudited)(in
thousands, except share and per share data) |
|
|
|
|
|
|
|
|
|
Three Months Ended December
31, |
|
|
Years Ended December 31, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Revenue |
|
$ |
18,751 |
|
|
$ |
20,543 |
|
|
$ |
81,056 |
|
|
$ |
71,331 |
|
Cost of goods sold |
|
|
2,776 |
|
|
|
3,665 |
|
|
|
11,881 |
|
|
|
12,361 |
|
Gross profit |
|
|
15,975 |
|
|
|
16,878 |
|
|
|
69,175 |
|
|
|
58,970 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
3,427 |
|
|
|
5,233 |
|
|
|
17,556 |
|
|
|
22,859 |
|
Selling, general and administrative |
|
|
23,658 |
|
|
|
28,698 |
|
|
|
108,893 |
|
|
|
120,065 |
|
Total operating expenses |
|
|
27,085 |
|
|
|
33,931 |
|
|
|
126,449 |
|
|
|
142,924 |
|
Loss from operations |
|
|
(11,110 |
) |
|
|
(17,053 |
) |
|
|
(57,274 |
) |
|
|
(83,954 |
) |
Interest expense |
|
|
(1,351 |
) |
|
|
(1,223 |
) |
|
|
(5,408 |
) |
|
|
(4,466 |
) |
Other income (expense), net |
|
|
1,780 |
|
|
|
1,379 |
|
|
|
7,245 |
|
|
|
2,225 |
|
Loss before income taxes |
|
|
(10,681 |
) |
|
|
(16,897 |
) |
|
|
(55,437 |
) |
|
|
(86,195 |
) |
Provision for income taxes |
|
|
10 |
|
|
|
10 |
|
|
|
110 |
|
|
|
47 |
|
Net loss and comprehensive
loss |
|
$ |
(10,691 |
) |
|
$ |
(16,907 |
) |
|
$ |
(55,547 |
) |
|
$ |
(86,242 |
) |
Net loss per share attributable
to common stockholders, basic and diluted |
|
$ |
(0.22 |
) |
|
$ |
(0.35 |
) |
|
$ |
(1.14 |
) |
|
$ |
(1.80 |
) |
Weighted-average shares used in
computing net loss per share attributable to common stockholders,
basic and diluted |
|
|
48,897,261 |
|
|
|
48,205,775 |
|
|
|
48,628,940 |
|
|
|
47,849,058 |
|
SIGHT
SCIENCES, INC.Gross Margin Disaggregation
(Unaudited)(in thousands) |
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|
|
Years Ended December 31, |
|
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
Surgical Glaucoma |
|
$ |
17,152 |
|
|
$ |
18,752 |
|
|
$ |
74,310 |
|
|
$ |
65,594 |
|
|
Dry Eye |
|
|
1,599 |
|
|
|
1,791 |
|
|
|
6,746 |
|
|
|
5,737 |
|
|
Total |
|
|
18,751 |
|
|
|
20,543 |
|
|
|
81,056 |
|
|
|
71,331 |
|
|
Cost of goods
sold |
|
|
|
|
|
|
|
|
|
|
|
|
|
Surgical Glaucoma |
|
|
2,022 |
|
|
|
2,923 |
|
|
|
8,830 |
|
|
|
8,295 |
|
|
Dry Eye |
|
|
754 |
|
|
|
742 |
|
|
|
3,051 |
|
|
|
4,066 |
|
|
Total |
|
|
2,776 |
|
|
|
3,665 |
|
|
|
11,881 |
|
|
|
12,361 |
|
|
Gross
profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
Surgical Glaucoma |
|
|
15,130 |
|
|
|
15,829 |
|
|
|
65,480 |
|
|
|
57,299 |
|
|
Dry Eye |
|
|
845 |
|
|
|
1,049 |
|
|
|
3,695 |
|
|
|
1,671 |
|
|
Total |
|
|
15,975 |
|
|
|
16,878 |
|
|
|
69,175 |
|
|
|
58,970 |
|
|
Gross
margin |
|
|
|
|
|
|
|
|
|
|
|
|
|
Surgical Glaucoma |
|
|
88.2 |
% |
|
|
84.4 |
% |
|
|
88.1 |
% |
|
|
87.4 |
% |
|
Dry Eye |
|
|
52.8 |
% |
|
|
58.6 |
% |
|
|
54.8 |
% |
|
|
29.1 |
% |
|
Total |
|
|
85.2 |
% |
|
|
82.2 |
% |
|
|
85.3 |
% |
|
|
82.7 |
% |
|
SIGHT SCIENCES, INC.GAAP to Non-GAAP
Reconciliation (Unaudited)(in
thousands) |
|
|
|
|
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
|
Years EndedDecember 31, |
|
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Operating expenses |
|
$ |
27,085 |
|
|
$ |
33,931 |
|
|
$ |
126,449 |
|
|
$ |
142,924 |
|
|
Less: Stock-based compensation |
|
|
(3,378 |
) |
|
|
(3,184 |
) |
|
|
(14,293 |
) |
|
|
(12,796 |
) |
|
Less: Depreciation & amortization |
|
|
(190 |
) |
|
|
(153 |
) |
|
|
(645 |
) |
|
|
(710 |
) |
|
Less: Restructuring costs |
|
|
(1,187 |
) |
|
|
— |
|
|
|
(1,187 |
) |
|
|
(939 |
) |
|
Adjusted Operating Expenses(4) |
|
|
22,330 |
|
|
|
30,594 |
|
|
|
110,324 |
|
|
|
128,479 |
|
|
4 Please see section titled "Non-GAAP Financial Measures" for
additional information.
SIGHT SCIENCES, INC.Supplemental Financial
Measures (Unaudited) |
|
|
|
|
|
|
Three Months EndedDecember
31, |
|
|
|
2023 |
|
|
2022 |
|
Surgical Glaucoma active customers(5) |
|
|
1,064 |
|
|
|
1,011 |
|
Dry Eye lid treatment units
sold(6) |
|
|
5,207 |
|
|
|
5,088 |
|
Dry Eye active customers(7) |
|
|
327 |
|
|
|
273 |
|
5 “Surgical Glaucoma active customers” means the number of
customers who ordered the OMNI Surgical System or the SION Surgical
Instrument during the three months ended December 31, 2023 and
2022.6 “Dry Eye lid treatment units sold” means the quantity of
TearCare SmartLids® sold during the three months ended December 31,
2023 and 2022.7 “Dry Eye active customers” means the number of
customers who ordered lid treatment units during the three months
ended December 31, 2023 and 2022.
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Oct 2023 to Oct 2024